[go: up one dir, main page]

IL146818A0 - New formulation - Google Patents

New formulation

Info

Publication number
IL146818A0
IL146818A0 IL14681800A IL14681800A IL146818A0 IL 146818 A0 IL146818 A0 IL 146818A0 IL 14681800 A IL14681800 A IL 14681800A IL 14681800 A IL14681800 A IL 14681800A IL 146818 A0 IL146818 A0 IL 146818A0
Authority
IL
Israel
Prior art keywords
omeprazole
dosage form
core material
new formulation
alkaline
Prior art date
Application number
IL14681800A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL146818A0 publication Critical patent/IL146818A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL14681800A 1999-06-22 2000-06-20 New formulation IL146818A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9902386A SE9902386D0 (sv) 1999-06-22 1999-06-22 New formulation
PCT/SE2000/001310 WO2000078293A1 (en) 1999-06-22 2000-06-20 New formulation

Publications (1)

Publication Number Publication Date
IL146818A0 true IL146818A0 (en) 2002-07-25

Family

ID=20416209

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14681800A IL146818A0 (en) 1999-06-22 2000-06-20 New formulation
IL146818A IL146818A (en) 1999-06-22 2001-11-29 Medicinal product containing as active substance omeprazole, S-omeprazole or its alkaline salts

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL146818A IL146818A (en) 1999-06-22 2001-11-29 Medicinal product containing as active substance omeprazole, S-omeprazole or its alkaline salts

Country Status (29)

Country Link
EP (1) EP1191926B1 (zh)
JP (1) JP2003502359A (zh)
KR (1) KR100717661B1 (zh)
CN (1) CN1243547C (zh)
AT (1) ATE291901T1 (zh)
AU (1) AU778158B2 (zh)
BR (1) BR0011894A (zh)
CA (1) CA2376226C (zh)
CZ (1) CZ20014579A3 (zh)
DE (1) DE60019116T2 (zh)
DK (1) DK1191926T3 (zh)
EE (1) EE200100693A (zh)
ES (1) ES2235912T3 (zh)
HK (1) HK1044480B (zh)
HU (1) HUP0201489A3 (zh)
IL (2) IL146818A0 (zh)
IS (1) IS6209A (zh)
MX (1) MXPA01012636A (zh)
NO (1) NO20016346L (zh)
NZ (1) NZ516186A (zh)
PL (1) PL352873A1 (zh)
PT (1) PT1191926E (zh)
RU (1) RU2240110C2 (zh)
SE (1) SE9902386D0 (zh)
SK (1) SK285326B6 (zh)
TR (1) TR200103693T2 (zh)
UA (1) UA73302C2 (zh)
WO (1) WO2000078293A1 (zh)
ZA (1) ZA200109803B (zh)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
DE60325709D1 (de) 2002-04-09 2009-02-26 Flamel Tech Sa Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
SI21402A (sl) 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
AU2004216405A1 (en) * 2003-02-28 2004-09-10 Ranbaxy Laboratories Limited Stable pharmaceutical composition of rabeprazole and processes for their preparation
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2005027876A1 (en) * 2003-08-28 2005-03-31 Ranbaxy Laboratories Limited Pharmaceutical compositions of benzimidazole and processes for their preparation
MXPA06002443A (es) * 2003-09-03 2006-08-31 Agi Therapeutics Ltd Formulaciones inhibidoras de la bomba de protones y metodos para preparar y utilizar tales formulaciones.
US8165651B2 (en) 2004-02-09 2012-04-24 Abbott Diabetes Care Inc. Analyte sensor, and associated system and method employing a catalytic agent
US7699964B2 (en) 2004-02-09 2010-04-20 Abbott Diabetes Care Inc. Membrane suitable for use in an analyte sensor, analyte sensor, and associated method
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2006022560A1 (en) * 2004-08-23 2006-03-02 Auckland Uniservices Limited Gastric therapies and compositions therefor
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
FR2885526B1 (fr) * 2005-05-13 2007-07-27 Flamel Technologies Sa Medicament oral a base d'inhibiteur de pompe a protons
NZ561375A (en) 2005-06-27 2011-06-30 Biovail Lab Int Srl Bupropion hydrobromide, and crystalline forms, compositions, and uses of this compound
MY151468A (en) * 2005-12-28 2014-05-30 Takeda Pharmaceutical Controlled release solid preparation
US7885698B2 (en) 2006-02-28 2011-02-08 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
JP5474541B2 (ja) 2006-07-25 2014-04-16 ベクタ・リミテッド 小さいジカルボン酸の誘導体と組み合わせてｐｐｉを用いる胃酸分泌を阻害する組成物および方法
EP2079448A2 (en) * 2006-10-10 2009-07-22 Dexcel Pharma Technologies Ltd. Improved release of statins in the intestine
CN102209529A (zh) 2008-09-09 2011-10-05 阿斯利康(瑞典)有限公司 将药物组合物递送至有需要的患者的方法
JP2012531409A (ja) 2009-06-25 2012-12-10 アストラゼネカ・アクチエボラーグ Ｎｓａｉｄ関連潰瘍を発症するリスクがある患者の処置方法
SG194943A1 (en) 2011-05-13 2013-12-30 Emotional Brain Bv Drug delivery system
EP2586429A1 (en) * 2011-10-26 2013-05-01 Freund Pharmatec Ltd. Multi-unit drug delivery device for pulsatile or sustained release
EA028049B1 (ru) 2011-12-28 2017-10-31 Поузен Инк. Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
WO2013122554A1 (en) 2012-02-14 2013-08-22 Mahmut Bilgic Pellet formulations comprising esomeprazole
CN103127026B (zh) * 2013-02-05 2017-02-15 悦康药业集团有限公司 一种奥美拉唑肠溶胶囊及其制备方法
EP3089666B1 (en) 2013-12-31 2020-08-19 Abbott Diabetes Care Inc. Self-powered analyte sensor and devices using the same
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
RU2614730C1 (ru) * 2016-02-05 2017-03-28 Игорь Юрьевич Чичерин Антибактериальное средство и способ лечения кишечного иерсиниоза, или псевдотуберкулеза, или эшерихиоза
US10736855B2 (en) * 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
JP6462625B2 (ja) * 2016-04-06 2019-01-30 ニプロ株式会社 カルシウムブロッカーを含有する錠剤
JP6426115B2 (ja) * 2016-04-06 2018-11-21 ニプロ株式会社 カルシウムブロッカーを含有する固形医薬組成物
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN109125282B (zh) * 2018-09-05 2020-07-14 珠海润都制药股份有限公司 一种奥美拉唑肠溶胶囊及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
EP0941074B1 (en) * 1996-11-06 2004-07-21 Wockhardt Europe Limited Delayed delivery system for acid-sensitive drugs
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
ES2362418T3 (es) * 1997-12-08 2011-07-05 Nycomed Gmbh Nueva forma de supositorio que comprende un compuesto activo ácido-lábil.
US7041313B1 (en) * 1998-08-12 2006-05-09 Altana Pharma Ag Oral administration form for pyridin-2-ylmethylsulfinyl-1H-benzimidazoles

Also Published As

Publication number Publication date
PL352873A1 (en) 2003-09-08
EP1191926B1 (en) 2005-03-30
RU2240110C2 (ru) 2004-11-20
CZ20014579A3 (cs) 2002-05-15
AU778158B2 (en) 2004-11-18
PT1191926E (pt) 2005-07-29
HK1044480A1 (en) 2002-10-25
BR0011894A (pt) 2002-04-02
CN1243547C (zh) 2006-03-01
ZA200109803B (en) 2003-02-28
IL146818A (en) 2007-10-31
NO20016346L (no) 2002-02-18
HUP0201489A2 (hu) 2002-11-28
IS6209A (is) 2001-12-21
WO2000078293A1 (en) 2000-12-28
DK1191926T3 (da) 2005-06-13
EP1191926A1 (en) 2002-04-03
TR200103693T2 (tr) 2002-05-21
DE60019116T2 (de) 2006-02-09
NO20016346D0 (no) 2001-12-21
DE60019116D1 (de) 2005-05-04
KR20020012002A (ko) 2002-02-09
CA2376226A1 (en) 2000-12-28
CA2376226C (en) 2009-10-20
ATE291901T1 (de) 2005-04-15
SK285326B6 (sk) 2006-11-03
KR100717661B1 (ko) 2007-05-14
SE9902386D0 (sv) 1999-06-22
SK18252001A3 (sk) 2002-09-10
NZ516186A (en) 2003-11-28
MXPA01012636A (es) 2002-06-21
JP2003502359A (ja) 2003-01-21
CN1356893A (zh) 2002-07-03
EE200100693A (et) 2003-02-17
AU6034400A (en) 2001-01-09
HUP0201489A3 (en) 2004-05-28
ES2235912T3 (es) 2005-07-16
HK1044480B (zh) 2005-08-26
UA73302C2 (en) 2005-07-15

Similar Documents

Publication Publication Date Title
IL146818A0 (en) New formulation
NO20012222L (no) Farmasöytisk formulering innbefattende omeprazol
MY129356A (en) Electrospun pharmaceutical compositions
YU60899A (sh) Farmaceutska formulacija omeprazola
AP2001002237A0 (en) Hydrogel-driven drug dosage form.
EE200000329A (et) Oraalne manustamisvorm happes ebapüsivate toimeainete tarbeks, selle valmistamismeetod ja happes ebapüsivat toimeainet sisaldava toimeaineühiku kasutamine
IL219820A0 (en) Hydrophilic controlled release formulation comprising pregelatinized starch for controlled release of an active component
HUP0203312A3 (en) Pharmaceutically active sulfonamide derivatives, process for their preparation, and pharmaceutical compositions and their use
IS4146A (is) Lyfjablanda til að gefa dýrum um munn sem inniheldur prótonupumpublokkara
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
GB9025372D0 (en) Pharmaceutical dosage forms
IE894049L (en) Therapeutically active substituted benzimidazole and process¹for its preparation
GB9905663D0 (en) Iodine preparation composition
ES2131482A1 (es) Formulacion acuosa de bambuterol.
MX9606041A (es) Forma de dosificacion de rapida disolucion.
MY127600A (en) Solid oral dosage forms of valsartan

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed